We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Collection of CTCs Improves Prostate Cancer Diagnosis

By LabMedica International staff writers
Posted on 16 Sep 2019
A recent paper described the benefits of circulating tumor cell (CTC) analysis for improving the diagnosis of aggressive prostate cancer beyond currently used PSA (prostate specific antigen) measurement, biopsy and/or MRI imagery.

PSA testing can result in unnecessary biopsies and over-diagnosis with consequent over-treatment. More...
Tissue biopsy is an invasive procedure, associated with significant risk of complications. More accurate non- or minimum-invasive diagnostic approaches are required to avoid unnecessary prostate biopsy and over-diagnosis.

Towards this end, investigators at Queen Mary University of London (United Kingdom) evaluated the potential of using circulating tumor cell analysis for prostate cancer diagnosis, particularly in predicting the presence of clinically significant prostate tumors in patients prior to biopsy.

The investigators used the ANGLE plc (Surrey, United Kingdom) Parsortix system to capture and analyze CTCs from 98 pre-biopsy and 155 newly diagnosed prostate cancer patients.

The Parsortix liquid biopsy process requires a blood sample - typically 10 milliliters in an EDTA vacutainer tube. As no pre-processing is required, the tube is simply attached to the Parsortix instrument. A Parsortix filtration cassette is inserted into the instrument and the system is primed for use. The instrument automatically passes the blood through the filtration cassette, and CTCs are caught in the cassette due to their larger size and lower compressibility as compared to other blood components.

Once trapped in the cassette, CTCs may be automatically stained with selected antibodies, which enables their identification and characterization. In addition, CTCs may be enumerated by placing the filtration cassette under a fluorescent microscope. Alternatively, cells may be eluted from the cassette and recovered in buffer solution for genomic analysis.

Results obtained with the Parsortix system indicated that the appearance of CTCs in pre-biopsy blood samples was indicative of the presence of aggressive prostate cancer. When the CTC tests results were combined with those of the current PSA test, the presence of aggressive prostate cancer in subsequent biopsies was predicted with accuracy of over 90%, better than any previously reported biomarkers.

Senior author Dr. Yong-Jie Lu, professor of molecular oncology at Queen Mary University of London said, "The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and over treatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure. Testing for circulating tumor cells is efficient, non-invasive, and potentially accurate, and we have now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer."

The study was published in the August 7, 2019, online edition of the Journal of Urology.

Related Links:
Queen Mary University of London
ANGLE plc


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.